Table 1.
Patient demographics and baseline clinical characteristics (modified intention‐to‐treat analysis set)
| Variable | Dulaglutide 1.5 mg (n = 184) | Dulaglutide 0.75 mg (n = 186) | Glimepiride (n = 186) | Total (n = 556) |
|---|---|---|---|---|
| Male, n (%) | 109 (59.2) | 107 (57.5) | 109 (58.6) | 325 (58.5) |
| Age, years (mean ± SD) | 52.8 ± 10.40 | 53.8 ± 9.83 | 52.7 ± 9.61 | 53.1 ± 9.95 |
| <65 years, n (%) | 167 (90.8) | 163 (87.6) | 172 (92.5) | 502 (90.3) |
| ≥65 years, n (%) | 17 (9.2) | 23 (12.4) | 14 (7.5) | 54 (9.7) |
| Bodyweight (kg) | 69.7 ± 10.8 | 70.7 ± 12.0 | 69.1 ± 10.6 | 69.8 ± 11.1 |
| BMI (kg/m2) | 25.5 ± 3.21 | 26.0 ± 3.34† | 25.3 ± 2.92 | 25.6 ± 3.17 |
| HbA1c, % (mean ± SD) | 8.0 ± 1.00 | 8.0 ± 1.01 | 7.9 ± 1.01 | 8.0 ± 1.00 |
| <8.5%, n (%) | 129 (70.1) | 127 (68.3) | 134 (72.0) | 390 (70.1) |
| ≥8.5, n (%) | 55 (29.9) | 59 (31.7) | 52 (28.0) | 166 (29.9) |
| Duration of T2D (years) | 4.0 ± 4.67 | 3.2 ± 4.00 | 3.6 ± 4.10‡ | 3.6 ± 4.26 |
| History of ≥1 previous OAM | ||||
| Yes, n (%) | 97 (52.7) | 96 (51.6) | 99 (53.2) | 292 (52.5) |
| Current alcohol use, n (%) | 41 (22.3) | 33 (17.7) | 34 (18.4)§ | 108 (19.5) |
| Current tobacco use,* n (%) | 64 (35.2)¶ | 41 (22.0) | 49 (26.5)†† | 154 (27.8) |
| Systolic BP (mmHg) | 129 ± 13.2 | 129 ± 13.9 | 128 ± 15.0 | 128 ± 14.0 |
| Diastolic BP (mmHg) | 79 ± 9.0 | 79 ± 9.4 | 78 ± 8.8 | 78 ± 9.1 |
| Pulse rate (b.p.m.) | 76 ± 10.1 | 75 ± 9.1 | 77 ± 9.6 | 76 ± 9.6 |
Data are presented as the mean ± standard deviation, except where indicated. *P < 0.05 based on Fisher's exact test. † n = 185; ‡ n = 185; § n = 185; ¶ n = 182; †† n = 185. BMI, body mass index; BP, blood pressure; HbA1c, glycated hemoglobin; OAM, oral antidiabetic medication; SD, standard deviation; T2D, type 2 diabetes.